Open AccessP562: LEMZOPARLIMAB (LEMZO) WITH VENETOCLAX (VEN) AND/OR AZACITIDINE (AZA) IN PATIENTS (PTS) WITH ACUTE MYELOID LEUKEMIA (AML) OR MYELODYSPLASTIC SYNDROMES (MDS): A PHASE 1B DOSE ESCALATION STUDY
Author(s) -
Hou J.Z.,
Daver N. G.,
Stevens D. A.,
Yamauchi T.,
Moshe Y.,
Fong C. Y.,
Marzocchetti A.,
Adamec R.,
Patel M.,
Lambert S.,
Wu K. Y.,
Röllig C.
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000845136.98578.78
Subject(s) - medicine , ven , oncology , azacitidine , myelodysplastic syndromes , venetoclax , adverse effect , bone marrow , leukemia , gastroenterology , chronic lymphocytic leukemia , biochemistry , gene expression , chemistry , computer security , computer science , dna methylation , gene